Spyre Therapeutics Inc (SYRE)

SG&A Expense Growth

4.66%

Fiscal year · Period ending:

SYRE logo

SYRE SG&A Expense Growth

Latest reported4.66%
SYRE FY SG&A Growth (YoY) (0.00% → 4.66%)
High-resolution chart · PNG

SYRE sg&a expense growth history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.

Spyre Therapeutics Inc SG&A Expense Growth — Annual fiscal periods
Period endingSG&A Expense Growth
4.6596%
14.5947%
40.0091%
4.4365%
35.1155%
36.3109%
17.424%
25.4918%
19.9619%
41.0964%
189.3917%
0%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.